We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Smith & Nephew Sinks After Covid-19 Hits Earnings

Thu, 18th Feb 2021 08:51

(Alliance News) - Stock prices in London opened mixed on Thursday with Smith & Nephew, domestic banks and a slew of ex-dividends shares weighing on the FTSE 100.

London's blue-chip index was down 20.05 points, or 0.3%, at 6,690.85. The FTSE 250 index was up 60.16 points, or 0.3%, at 21,209.65, and the AIM All-Share index was flat at 1,222.95.

The Cboe UK 100 index was up 0.1% at 667.81 points. The Cboe 250 was up 0.1% at 18,716.02, but the Cboe Small Companies was flat at 12,818.71.

The CAC 40 index in Paris was up 0.1% and Frankfurt's DAX 30 was 0.3% higher.

In the FTSE 100, Ashtead Group was the best performer, up 3.1% after Goldman Sachs started coverage on the equipment rental firm with a Buy rating.

Aviva was up 1.5% after Citigroup upgraded the insurer to Buy from Neutral.

At the other end of the large-caps, Smith & Nephew was the worst performer, 7.5% lower. The medical devices maker reported a fall in annual earnings, as the coronavirus pandemic caused elective surgical procedures to be put on hold.

For 2020, revenue was down 11% to USD4.56 billion from USD5.14 billion in 2019 and trading profit fell sharply to USD683 million from USD1.17 billion. The company declared a full-year dividend of 37.5 US cents per share, unchanged from 2019.

Looking ahead to 2021, Smith & Nephew said the outlook reflects the likely continuation of Covid-19 effects during the first half of 2021 and the uncertainty regarding the timing and pace of recovery.

Imperial Brands, GlaxoSmithKline, BP and Royal Dutch Shell 'A' and 'B' shares were down 4.0%, 2.5%, 0.4%, 0.6% and 0.7%, respectively. The stocks went ex-dividend meaning new buyers no longer qualify for the latest payout.

NatWest Group was 1.5% lower. The Financial Times reported that the UK state-backed lender is gearing up to gradually withdraw from the Republic of Ireland, with the aim of freeing up capital and moving completely to the UK market.

Peer Barclays was down 1.1% after the bank reported a drop in annual earnings - with profit falling by almost a third in 2020.

However, Barclays said it would resume dividend payments after the Bank of England lifted its ban on shareholder distributions in December.

For 2020, Barclays posted net income of GBP21.77 billion, up 1% from GBP21.63 billion in 2019, as net interest income fell 14% to GBP8.12 billion from GBP9.41 billion.

Barclays booked GBP4.84 billion in credit impairments in 2020, more than doubled from GBP1.91 billion in 2019.

Pretax profit sank 30% to GBP3.07 billion from GBP4.36 billion. However, the figure beat company-compiled consensus which forecast pretax profit of GBP2.81 billion.

Barclays declared a dividend of 1.0 pence for 2020, down from 3.0p paid in 2019. In addition, Barclays said it intends to initiate a share buyback of up to GBP700 million, which is expected to commence in the first quarter of 2021.

Richard Hunter, head of Markets at interactive investor, commented: "The results are far from perfect, but in opening the reporting season Barclays has set the bar high for its rivals. The unavoidable spectre of the pandemic dominates the figures.

"Group income for the year rose by 1%, propelled by a rise of 22% in the Corporate Investment Bank and offsetting the declines of 22% in Consumer Cards & Payments and 14% in Barclays UK. As customers have battened down the hatches in depositing more with the bank, they have also attempted to pay down credit card debt, for example, both of which drag on the bank's income."

Fellow UK bank Lloyds was 1.8% lower.

The pound was quoted at USD1.3875 early Thursday, up from USD1.3845 at the London equities close Wednesday.

The euro was priced at USD1.2050, higher against USD1.2036. Against the yen, the dollar was trading at JPY105.81, flat from JPY105.82.

Brent oil was quoted at USD65.01 a barrel Thursday morning, up sharply from USD63.53 late Wednesday, as US refining and extraction capacity remains shuttered due to deadly wintry conditions in Texas.

Gold was trading at USD1,783.15 an ounce, higher versus USD1,774.53.

The Japanese Nikkei 225 index closed down 0.2% on Thursday. In China, the Shanghai Composite ended up 0.6%, while the Hang Seng index in Hong Kong ended down 1.5%. Financial markets in Shanghai reopened after being closed over the past week for the Lunar New Year holiday. The S&P/ASX 200 in Sydney ended flat.

In the economic calendar for Thursday, there is Irish inflation at 1100 GMT and US initial jobless claims at 1330 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.